Methods and compositions for the treatment of metabolic disorders

Abstract

The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.

1 .- 83 . (canceled) 
     
     
         84 . A method for treating a subject with hyperphenylalaninemia comprising administering to said subject a therapeutically effective amount of tetrahydrobiopterin (BH4) or pharmaceutically acceptable salt thereof, wherein the BH4 is administered orally once per day. 
     
     
         85 . The method of  claim 84 , wherein the hyperphenylalaninemia results from BH4 deficiency. 
     
     
         86 . The method of  claim 84 , wherein said subject is administered BH4 for at least 7 days. 
     
     
         87 . The method of  claim 84 , wherein the subject is administered BH4 for at least 2 weeks. 
     
     
         88 . The method of  claim 84 , wherein said subject is administered BH4 for at least 6 weeks. 
     
     
         89 . The method of  claim 84 , wherein said subject has a plasma phenylalanine concentration of greater than 180 μM prior to treatment with BH4. 
     
     
         90 . The method of  claim 84 , wherein said subject has a plasma phenylalanine concentration of greater than 600 μM prior to treatment with BH4. 
     
     
         91 . The method of  claim 84 , wherein said subject has a plasma phenylalanine concentration of greater than 1000 μM prior to treatment with BH4. 
     
     
         92 . The method of  claim 84 , wherein said subject has a plasma phenylalanine concentration of greater than 1200 μM prior to treatment with BH4. 
     
     
         93 . The method of  claim 84 , wherein said administration of BH4 decreases the plasma phenylalanine concentration of said subject to less than 600 μM. 
     
     
         94 . The method of  claim 84 , wherein said administration of BH4 decreases the plasma phenylalanine concentration of said subject to less than 500 μM. 
     
     
         95 . The method of  claim 84 , wherein said administration of BH4 decreases the plasma phenylalanine concentration of said subject to less than 360 μM. 
     
     
         96 . The method of  claim 84 , wherein said BH4 is administered in a daily dose of between about 1 mg/kg to about 30 mg/kg. 
     
     
         97 . The method of  claim 84 , wherein said BH4 is administered in a daily dose of between about 5 mg/kg to about 30 mg/kg. 
     
     
         98 . The method of  claim 84 , wherein said BH4 is administered as a crystallized form stable for at least 3 months at 40° C. and 75% relative humidity. 
     
     
         99 . The method of  claim 100 , wherein said crystallized form of BH4 comprises at least 99.5% pure (6R)-5,6,7,8-tetrahydrobiopterin. 
     
     
         100 . The method of  claim 84 , further comprising administering to said subject a protein-restricted diet. 
     
     
         101 . The method of  claim 102 , wherein said protein-restricted diet is a phenylalanine-restricted diet wherein the total phenylalanine is restricted to less than 600 mg per day. 
     
     
         102 . The method of  claim 102 , wherein said protein-restricted diet is a phenylalanine-restricted diet wherein the total phenylalanine is restricted to less than 300 mg per day. 
     
     
         103 . The method of  claim 102 , wherein said subject is a pregnant female. 
     
     
         104 . The method of  claim 102 , wherein said subject is an infant between the ages of 0 and 3 years of age. 
     
     
         105 . The method of  claim 102 , wherein said subject is a female of child-bearing age that is contemplating pregnancy.